Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer

被引：0
|
作者：
Gajria, D. [1 ]
King, T. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Modi, S. [1 ]
Drullinsky, P. [1 ]
Syldor, A. [1 ]
Path, S. [1 ]
Seidman, A. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-04
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
    Seiler, Milton
    Ray-Coquard, Isabelle
    Melichar, Bohuslav
    Yardley, Denise A.
    Wang, Rui X.
    Dodion, Pierre F.
    Lee, Mark A.
    CLINICAL BREAST CANCER, 2015, 15 (01) : 60 - 65
  • [2] Relapsed/Refractory HER2+Metastatic Breast Cancer
    Brufsky, Adam M.
    Gadi, V. K.
    Hurvitz, Sara A.
    Iyengar, Neil M.
    ONCOLOGY-NEW YORK, 2021, 35 (04): : 215 - 219
  • [3] Targeting HER2 in breast cancer: beyond trastuzumab
    EP Winer
    Breast Cancer Research, 13
  • [4] Targeting HER2 in breast cancer: beyond trastuzumab
    Winer, F. P.
    BREAST CANCER RESEARCH, 2011, 13
  • [5] Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+metastatic breast cancer
    Wu, Y.
    Amonkar, M. M.
    Sherrill, B. H.
    O'Shaughnessy, J.
    Ellis, C.
    Baselga, J.
    Blackwell, K. L.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2582 - 2590
  • [6] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [7] HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast
    Han, S.
    Ro, J.
    Paquet, A.
    Huang, W.
    Weidler, J.
    Lee, K. S.
    Park, I.
    Oh, D.
    Im, S.
    Kim, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
    Andrieu, Charlotte
    Al-Sultan, Dalal
    Ivers, Laura
    Pina, Jose Javier Berenguer
    Skrobo, Darko
    Ballot, Josephine
    Eustace, Alex J.
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
12345